PDCD1 and melanoma: ,16 Indeed, the most recent long-term outcomes (6.5 years) of melanoma patients treated with immune checkpoint inhibitors showed median progression free survival (PFS) of 11.5 months for combination anti-CTLA-4/PD-1, 6.9 months for anti-PD-1 and 2.9 months for anti-CTLA-4.10